Menu Search
Equities

Medpace Holdings Inc

01P:BER

Medpace Holdings Inc

Actions
  • Price (EUR)325.50
  • Today's Change-0.50 / -0.15%
  • Shares traded12.00
  • 1 Year change+27.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

  • Revenue in USD (TTM)2.07bn
  • Net income in USD365.57m
  • Incorporated2014
  • Employees5.90k
  • Location
    Medpace Holdings Inc5375 Medpace WayCINCINNATI 45227-1543United StatesUSA
  • Phone+1 (513) 579-9911
  • Fax+1 (302) 655-5049
  • Websitehttps://investor.medpace.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.